Pediatric Asthma

**With Dr. Dennis Scolnik & Dr. Sanjay Mehta**
Prepared by Dr. Anton Helman, April 2016

**Pediatric Asthma Severity Indicators**

- life-threatening exacerbations
- admissions to ICU
- intubation
- deterioration while already on systemic steroids
- using more than 2 canisters of short acting B-agonist per month
- cardiopulmonary and psychiatric comorbidities

It's important to realize that a lack of risk factors does not necessarily confer a lack of risk, so even if a patient has none of these risk factors, they can still be at risk for deterioration from their asthma.
**VBG in Pediatric Asthma**

A PaCO2 >42 is indicative but not diagnostic of a severe exacerbation.

A PaCO2 >50 is a risk factor for impending respiratory failure.

Metabolic Acidosis is an indicator of impending arrest!

A VBG is seldom indicated unless the child has no clinical improvement with maximal therapy. The timing of the VBG is important: It may be most useful as a baseline after ED treatment in a patient going to the ICU.

Don't forget the classic teaching: A 'normal' Hg partial pressure of CO2 in a patient with extreme tachypnea and retractions could indicate impaired ventilation and impending respiratory failure.

**Indications for CXR in presumed Pediatric Asthma**

The rate of CXR use in kids with asthma increased significantly from the mid 90's to around 2010. Although it's not unreasonable for first time wheezers to get a baseline CXR, it's important to realize that an unsuspected diagnosis made on the basis of a CXR in an acutely wheezing child is rare, even if the child has never wheezed before. **In fact there are no set of predictors** in the literature that can accurately identify children likely to have abnormalities on CXR. Nonetheless, some situations that might warrant a CXR in a child with a wheeze, are focal chest findings, fever, subcutaneous emphysema or a history of choking.

**MDI vs Nebs vs IV B-agonists in Pediatric Asthma**

Compared with nebulized treatments, metered-dose inhaler (MDI) with a spacer use has been shown to be equally effective for children of all ages with a wide range of illness severity and by multiple outcome measures. Among children 1 to 4 years old, using a MDI with a spacer was associated with a greater reduction in wheezing and a lower hospitalization rate in one study. Furthermore, a recent cost analysis determined that the use of MDIs to treat children with mild to moderate asthma exacerbations in the ED could yield significant cost savings compared with nebulized treatments. MDIs with a spacer should not be used in patients with impending respiratory failure and it can be difficult to coordinate breathing with administration of the inhaler for patients less than 1 year old.
IV beta-agonists have not been shown to be superior to inhaled beta-agonists. IV beta-agonists should be considered in those who are unable to tolerate nebulized or MDI treatments.

For < 15 kg: Salbutamol MDI 4 puffs or 2.5mg nebulized in 2-3ml NS x3 back to back (continuously)

For > 15kg: Salbutamol MDI 8 puffs or 5mg nebulized in 2-3ml NS x3 back to back (continuously)

A Cochrane review found that those treated with continuously nebulized bronchodilators had lower rates of hospitalization, greater improvements in pulmonary function test results, and similar rates of adverse events compared with those treated intermittently. Continuous treatment allows greater compliance with the goal of delivering the equivalent of three intermittent bronchodilator treatments in the first hour of care. In addition, this method will result in less respiratory therapy time and costs; it has been shown to be safe, and it may benefit the sickest patients the most.

**In children receiving multiple beta-agonist treatments, watch for hypokalemia, especially if the patient has diarrhea, or is on diuretic medications.**

B-agonists with Ipatropium Bromide are more effective than B-agonists alone in Pediatric Asthma

In a systematic review and meta-analysis comparing the use of beta-agonists plus anticholinergics with beta-agonists alone, combination therapy was associated with significantly lower hospitalization rates and improvements in asthma scores and pulmonary function test results.

So multiple doses of ipatropium bromide added to beta-agonists are indicated for kids with moderate to severe asthma exacerbations. However, there are no clinical trials supporting ipratropium use beyond the first hour or first 3 doses in children.

**Ipatromium Bromide dosing:** MDI 4 puffs (80mcg) or 250mcg nebulized

Single dose Dexamethasone is the preferred oral corticosteroid for Pediatric Asthma

A study out of the Annals of EM entitled “A Randomized Trial of Single-Dose Oral Dexamethasone Versus Multidose Prednisolone for Acute Exacerbations of Asthma in Children Who Attend the Emergency Department”, showed that a single dose of dexamethasone dosed at 0.3mg/kg orally compared to prednisolone dosed at 1mg/kg for 3 days in 245 children with known asthma had equivalent PRAM scores at day 4. This is
consistent with 3 previous RCTs, the largest of which dosed dexamethasone at 0.6mg/kg po.

So, it is reasonable to give one dose of dexamethasone at 0.3-0.6mg/kg po to all but the sickest of kids who present to the ED with an asthma exacerbation, obviating the need for an outpatient prescription.

It's also worth noting that dexamethasone is associated with less vomiting compared to prednisolone as well.

**Inhaled Steroids**

While there's no evidence that the use of inhaled steroids in the ED are beneficial there is evidence that they decrease relapse rates in the outpatient setting.

The maximum dose of inhaled steroid is the equivalent of Fluticasone (Flovent in Canada) of 100 micrograms 2 puffs twice daily for a maximum of 200 micrograms per day. There is evidence based on observational data from the Canadian Paediatric Surveillance Program that higher doses may lead to adrenal suppression and in some cases adrenal shock.

**Discharge Criteria**

Discharge criteria from the ED include:

- Needing beta-agonists less often than q4 h after 4 to 8 h of conventional treatment
- A reading of SpO2 94% on room air
- Minimal or no signs of respiratory distress
- Improved air entry

**Discharge Instructions**

- Prepare a written asthma action plan with medications and signs to look out for that would necessitate a return to the ED
- Continue to use a short-acting beta-agonists such as salbutamol (200 μg [0.3 puffs/kg to a maximum of 10 puffs] every 4 h) until exacerbations resolve and then as needed, with directions to see a health care professional if therapy is needed more often than every 4h.
- For all but the mildest of asthma patients seen in the ED, a prescription for 3 weeks of inhaled steroid such as fluticasone 50 micrograms, 2 puffs twice daily.
- Review techniques for using inhaled asthma medications as well as for cleaning/maintaining the inhaler device. Parents must understand that they need to use the MDI spacer and
that the mask fits properly, to use the B-agonist BEFORE the inhaled steroid and to wash the mouth out after the steroid inhaler to prevent thrush.

- Encourage follow-up with the patient’s primary care physician or a local asthma clinic to review asthma control, environmental history and symptom recognition.

**Peak expiratory flow should NOT be relied upon solely as a measure of severity or as a sole determinate for discharge.**

**IV Magnesium Sulphate**

A meta-analysis suggests that use of magnesium sulphate results in improved outcomes for both adults and children, improving respiratory function and decreasing hospital admissions. IV magnesium sulphate may be considered in cases of moderate and severe asthma with incomplete response to conventional. IV magnesium sulphate therapy should be initiated EARLY, within the first 1 to 2 hours of the ED visit.

The most common adverse effect is hypotension; this may be avoided by infusion of the dose over 20 minutes and giving a fluid bolus prior to or during the magnesium infusion.

If there is a delay in obtaining an IV, magnesium sulphate can be given IO or inhaled via nebulizer.

**What about nebulized MgSO4?**

The RCT entitled MAGNETIC trial in 2013 of about 500 children showed that MgSO4 2.5mL of 250mmol/L solution q20mins x 3 added to the salbutamol and ipratropium bromide nebulizer in the first hour for kids with acute severe asthma, significantly improved asthma severity scores without any increase in adverse events.

**Pediatric Asthma Therpay with Equivocal of Mixed Evidence that may be indicated when all else fails**

Up to 26% of children intubated due to asthma suffer complications including pneumothorax, impaired venous return, and cardiovascular collapse because of increased intrathoracic pressure. Mechanical ventilation during an asthma exacerbation is associated with an increased risk of death and should be considered as a last resort and in conjunction with the support of a paediatric ICU specialist.

**Heliox - reserve for the ICU**

According to the Canadian Pediatric Society Guidelines for Managing the Patient with Acute Asthma Exacerbation, using a helium-oxygen gas mixture should be reserved for children in the ICU setting with severe asthma exacerbation who have failed to improve despite maximized therapy.
A limited case series has reported the effectiveness of a bolus (2 mg/kg) followed by a continuous infusion (2 to 3 mg/kg/h) of ketamine in children with severe asthma who were approaching respiratory failure. In this study, the use of ketamine resulted in prompt improvement and avoided the need for endotracheal intubation. This is an appealing use of ketamine, because it may allow one to avoid the hazards of endotracheal intubation and mechanical ventilation in the patient with asthma.

A randomized control trial showed no improvement in pulmonary index scores with the administration of ketamine to patients with moderate to severe asthma. Patients were randomized to 0.2mg/kg ketamine bolus followed by 0.5mg/kg/h for 2 hours vs placebo. Pulmonary index scores were measured throughout the 2 hours and no difference was found.

In a 2001 prospective, observational, single-arm pilot study in two pediatric EDs over three months, the effect of IV ketamine added to standard therapy in status asthmaticus was evaluated. Initiation of ketamine in patients with severe asthma was associated with clinical improvement. Side effects were easily managed with treatment or discontinuation of ketamine.

The take home message is that more convincing evidence is required before ketamine can be recommended for routine treatment of severe pediatric asthma to avoid intubation. Ketamine, however, is safe at dissociative dosages, and is a reasonable option when all others measures have failed.

**BiPAP - the pediatric literature isn't quite as impressive as the adult literature**

A few case reports and observational studies of the use of BiPAP in pediatric asthma show some promise. The one RCT of only 20 patients does show a benefit in clinical asthma scores, respiratory rate, and supplemental oxygen need. While intuitively sensible, there is no evidence that NIPPV prevents the need for intubation in children with status asthmaticus.

Similar to other rescue measures, NIPPV can be considered when all others measures have failed in hopes of avoiding endotracheal intubation.

**High Flow Nasal Cannula - gaining popularity**

Another way of providing a bit of noninvasive positive pressure that seems to becoming popular among the pediatricians is high flow nasal cannula oxygen. The evidence is conflicting for this, and most studies were done in kids with bronchiolitis rather than asthma. One study from *Pediatric Emergency Care* in 2012 showed that the use of high flow nasal oxygen reduced the need for intubation in pediatric acute respiratory failure, but there was no change in mortality or ICU length of stay.

However, a Cochrane review in 2014 based on 11 studies concluded that no evidence could be found to allow determination of the safety or effectiveness of HFNC therapy in children. The latest study out of *Emergency Medicine Journal* concluded that HFNC may have a role, but about 1/3 of patients required BiPAP or intubation.
The decision to intubate should be based on clinical judgement as opposed to any single vital sign or blood gas result. Some variables to consider for intubation are worsening hypercapnea, patient exhaustion and changes in mental status.

Putting it all together for Severe Pediatric Asthma Exacerbation: A Step-wise Approach

*note that the blue indicates evidence-based treatment while the red indicates therapies that are reasonable to try when all else has failed but do not have strong evidence for benefit*

- Put the child on the cardiac monitor
- Obtain IV access and draw blood work including electrolytes and a VBG (with particular attention to the K)
- Call your RT and pediatric intensivist early
- Continuous salbutamol nebulizers with the first 3 including ipratropium bromide
- IV steroids: methylprednisolone 1mg/kg or hydrocortisone 5mg/kg
- IV NS 20mL/kg bolus (preferably before the MgSO4)
- IV Magnesium Sulphate 40mg/kg to a maximum of 2g over 20 mins (in the first hour if possible)

Consider epinephrine 0.01mg/kg IM and nebulized MgSO4 (especially if you are having trouble obtaining IV access)

Consider BiPaP or high flow nasal oxygen

Consider IV salbutamol

Consider subdissociative dose ketamine

Consider Heliox

Quote of the Month

"Knowledge is not only power; it is happiness, and being taught is the intellectual analog of being loved."

- Isaac Asimov

Dr. Helman, Dr. Mehta and Dr. Scolnik have no conflicts of interest to declare
Key References